Group 1 - The core viewpoint of the article highlights the rapid development of protein degradation technology in the field of autoimmune diseases, with significant attention on small molecule targets such as STAT6, IRAK4, IRF5, VAV1, NLRP3, and NEK7, which show promising efficacy and safety in clinical or preclinical stages [1] - From 2026 onwards, numerous autoimmune TPD targets are expected to yield data readouts or enter critical clinical phases, indicating a potential area of investment focus [1] - In the medical device sector, there is an emphasis on inventory replenishment and bidding for surgical robots and endoscopes, while innovative consumables benefiting from centralized procurement in areas like neurointervention, peripheral intervention, and electrophysiology are also highlighted [1] Group 2 - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on the high growth and innovation in the biotech industry [1] - The index reflects the performance and market value of companies engaged in the research, development, and production of innovative drugs, emphasizing the significance of new drug development in the biopharmaceutical sector [1]
20cm速递｜创新药板块持续回调，科创创新药ETF国泰（589720）回调近2%，回调或可布局
Mei Ri Jing Ji Xin Wen·2026-02-26 05:57